KRAS and neoplasm: Interestingly, KRAS mutations, particularly the most prevalent subtype G12C, when co-existing with PD-L1 expression in patients’ tumour were shown to have poor prognosis56, supporting the potential benefit of KRAS mutation testing in selecting patients for immunotherapy using check-point inhibitor.